The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Chyawanprash Special will be available at all Jan Aushadhi Kendras
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
The Government of India is supporting the states in active case detection, surveillance, treatment, supply of diagnostic kits, medicines, sprays etc.
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
To create leading company developing medicines targeting metalloenzymes
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Subscribe To Our Newsletter & Stay Updated
